Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Now that the year is underway and a new presidential administration is in place in Washington, let’s consider the environment ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $1.12 billion, announced a recent change to its Board ...

NORTHFIELD, Minn., Jan. 28, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leading manufacturer of animal health products, is excited to announce the appointment of Stephanie Hastings as its new ...

VANCOUVER - In a significant development for its proprietary small molecule drug candidates, InMed Pharmaceuticals Inc. (NASDAQ: INM), a $3.6 million market cap pharmaceutical company dedicated to ...

AAA-604 is under clinical development by Novartis and currently ... proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

AAA-604 is under clinical development by Novartis and currently ... proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for almost a third of exports - during Donald Trump’s presidency.

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI stocks. In the third quarter of 2024, investment titan Blackrock ...